18F-DCFPyL

Phase 2Radiopharmaceutical

UUniversity of Wisconsin, Madison

18F-DCFPyL is one of 116 therapeutic programs targeting Metastatic Prostate Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

115

Competitors

Pipeline

Status by Indication[2][1]

Indication

Metastatic Prostate CancerActive, not recruiting

Breast CancerRecruiting

Prostate CancerActive, not recruiting

Prostate NeoplasmsActive, not recruiting

Localized Prostate CancerRecruiting

Prostatic NeoplasmsRecruiting

Metastatic Prostate CancerPhase 2

Active, not recruiting

Breast CancerPhase 2

Recruiting

Prostate CancerPhase 2

Active, not recruiting

Prostate NeoplasmsPhase 2

Active, not recruiting

Localized Prostate CancerPhase 2

Recruiting

Prostatic NeoplasmsPhase 2

Recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

18F-DCFPyL

UUniversity of Wisconsin, Madison

Phase 2

1 2

Adriamycin

GGynecologic Oncology Group

Preclinical

87 3

Gemzar

GGynecologic Oncology Group

Preclinical

22 4

Aquasol E

NNational Eye Institute (NEI)

Preclinical

—5

Apatinib Mesylate

BBukwang Pharmaceutical

Preclinical

3 6

Recombinant Human Endostatin

PPeking University Third Hospital

Preclinical

1 7

Metfomin

UUniversity of Texas Southwestern Medical Center

Preclinical

1 8

Diuretic

RReprieve Cardiovascular, Inc

Preclinical

1 9

Tianeptine

Pfizer

Preclinical

1 10

Lipegfilgrastim

Merck & Co.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Active, not recruiting

Prostate Cancer

NCT03976843

Recruiting

Prostate Cancer

NCT05588128

Q1 2028

Phase 2Active, not recruiting

Metastatic Prostate Cancer

NCT03173924

Q4 2029

Phase 2Recruiting

Localized Prostate Cancer

NCT05155046

Q1 2031

Phase 2Active, not recruiting

Prostate Neoplasms

NCT03181867

Clinical

Trials by Indication[1]

Prostate Cancer2 trials

A Study of Prospective Monitoring of Subjects With Biochemically Recurrent Prostate Cancer Using 18F-DCFPyL

Recruiting·NNational Cancer Institute (NCI)··NCT05588128·350 enrolled

A Phase II Multi-Institutional Trial to Evaluate Prostate Specific Membrane Antigen (PMSA)-Based PET Imaging of High Risk Prostate Cancer

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT03976843·175 enrolled

Prostatic Neoplasms1 trial

A Phase II Trial of Focal Ultrahypofractionated Stereotactic Radiation Therapy for the Treatment of Unifocal Prostate Cancer

Recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT05616650·42 enrolled

Breast Cancer1 trial

Evaluation of Prostate Specific Membrane Antigen (PSMA) in HER2-negative, Androgen Receptor (AR)-Positive Metastatic Breast Cancer With 18F-DCFPyL PSMA-based PET/CT

Recruiting·UUniversity of Wisconsin, Madison·Phase 2·NCT04573231·13 enrolled

Prostate Neoplasms1 trial

18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT03181867·360 enrolled

Metastatic Prostate Cancer1 trial

Evaluation of 18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT03173924·96 enrolled

1 more indication

Localized Prostate Cancer1 trial

Phase II Trial of 18F-DCFPyL Imaging as a Method to Assess Treatment Response to Stereotactic Body Radiation Therapy

Recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT05155046·130 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for 18F-DCFPyL. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for 18F-DCFPyL. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — University of Wisconsin, Madison company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Radiopharmaceutical
Highest Phase: Phase 2[1]
Company: UUniversity of Wisconsin, Madison

18F-DCFPyL

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q1 2028

Q4 2029

Q1 2031

Trials by Indication[1]

Prostate Cancer2 trials

Prostatic Neoplasms1 trial

Breast Cancer1 trial

Prostate Neoplasms1 trial

Metastatic Prostate Cancer1 trial

Localized Prostate Cancer1 trial

References

Drug Info

Quick Facts

Related News